Patents Examined by Jennifer S Spence
  • Patent number: 11981933
    Abstract: Devices, systems, and techniques are described for printing pre-aligned microtissues into larger tissue constructs. For example, a method of printing a tissue construct includes aligning cells in a first direction to create pre-aligned microtissues, suspending the pre-aligned microtissues in a liquid to create a bioink, and depositing the pre-aligned microtissues in a second direction to create the tissue construct.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: May 14, 2024
    Assignee: Regents of the University of Minnesota
    Inventors: Caleb Darwin Vogt, Angela Panoskaltsis-Mortari
  • Patent number: 11976297
    Abstract: The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors, that exhibit cross-talk between the receptors.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: May 7, 2024
    Assignee: A2 BIOTHERAPEUTICS, INC.
    Inventor: Alexander Kamb
  • Patent number: 11970713
    Abstract: The invention relates to a method for long-term ex vivo maintenance or expansion of one or more of a human erythroblast, a human megakaryocyte-erythroid progenitor, or a human common myeloid progenitor, comprising the step of: culturing cells comprising one or more of those cells in a culture medium comprising one or more selected from a tankyrase inhibitor, a growth factor, a B-Raf kinase inhibitor and a GSK-3 inhibitor.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: April 30, 2024
    Assignee: OCGENE THERAPEUTICS CORPORATION
    Inventors: Chang Tong, Yibin Lin, Kangtao Lv
  • Patent number: 11946070
    Abstract: The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: April 2, 2024
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Duk Lyul Na, Jong Wook Chang, Hyo Jin Son
  • Patent number: 11918687
    Abstract: Disclosed herein are compositions comprising isolated exosomes, for instance exosomes wherein at least 20% of the exosomes comprise SDC2, methods of isolation, and methods of use.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: March 5, 2024
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Jack Kavanaugh, Larry Couture
  • Patent number: 11911450
    Abstract: The invention provides a method of treating or preventing pain in a subject in need thereof. The method comprising administering to the subject an expression vector comprising a nucleic acid sequence encoding carbonic anhydrase (10) or carbonic anhydrase (11) such that the nucleic acid is expressed to produce carbonic anhydrase (10) or carbonic anhydrase (11). Alternatively, the method comprising administering to the subject an expression vector comprising a nucleic acid sequence encoding a carbonic anhydrase (8) fragment such that the nucleic acid is expressed to produce the carbonic anhydrase (8) fragment.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: February 27, 2024
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Roy Levitt, Gerald Z. Zhuang
  • Patent number: 11913020
    Abstract: The present invention relates to a medium composition for improving stem cell migration, which includes ethionamide, and a use thereof. According to the present invention, the migration of stem cells may be effectively improved by the adjustment of a culture environment, which is a simple and safe method, without using gene manipulation or a viral vector, and the stem cells improved in migration by the method may be effectively used as a stem cell therapeutic agent that is able to function by rapidly migrating to the damaged region after transplantation.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: February 27, 2024
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Duk Lyul Na, Jong Wook Chang, Hyo Jin Son
  • Patent number: 11891615
    Abstract: A method of producing Klotho protein includes preparing a Klotho plasmid DNA vector, culturing cells, transfecting the cells with the Klotho plasmid DNA vector in a cell culture medium, growing the transfected cells, and harvesting the cell culture supernatant by removing the transfected cells. The Klotho plasmid DNA vector has a mammalian selection marker and a Klotho open reading frame. The cells are primary fibroblast cells and/or mesenchymal stromal cells. A method of manufacturing a cosmetic composition includes combining Klotho protein or the cell culture supernatant with a cosmetically acceptable vehicle. A method of treating a patient to improve the condition and appearance of aging skin includes topically administering the cosmetic composition to the patient. By upregulating the Klotho gene in vitro and incorporating the Klotho protein and growth factors into a composition, transepidermal water loss, skin atrophy, and free radical damage to the skin may be addressed.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: February 6, 2024
    Inventor: Gail Marion Humble
  • Patent number: 11891616
    Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to MeCP2 loss and/or misfunction, including RETT syndrome. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a MeCP2 polypeptide.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: February 6, 2024
    Assignee: Board of Regents of the University of Texas System
    Inventors: Steven J. Gray, Sarah Sinnett
  • Patent number: 11857575
    Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 2, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans, Javier Garcia Casado, Rebeca Blazquez Duran, Francisco Miguel Sanchez Margallo
  • Patent number: 11834640
    Abstract: Disclosed are devices for improving viability of isolated islets or ?-cells and stimulating insulin production from isolated islets or ?-cells and uses thereof for treating type 1 diabetes.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: December 5, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael Cho, Caleb Liebman
  • Patent number: 11826386
    Abstract: Disclosed are compositions and methods for targeted treatment of cancer. The present disclosure provides chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors are specific for a low density cancer antigen or peptide in groove antigen.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: November 28, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David DiLillo, Thomas Craig Meagher
  • Patent number: 11819554
    Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: November 21, 2023
    Assignees: UNIVERSITY OF MASSACHUSETTS, FULCRUM THERAPEUTICS, INC.
    Inventors: Michael R. Green, Minggang Fang, Walter Kowtoniuk
  • Patent number: 11806442
    Abstract: Periosteum harvesting and processing systems and methods enable rapid, efficient, and repeatable harvesting of periosteum tissue from human long bones and processing of the tissue into individual fibers for use in strengthening surgical allograft products. One harvesting and processing method involves providing a human long bone, securing the long bone between two rotating live centers, scraping, using one of a plurality of harvesting tools selected from a harvesting and processing kit, periosteum tissue from the long bone, executing a first wash cycle comprising a hydrogen peroxide wash, executing a second wash cycle comprising an isopropyl alcohol wash, executing a third wash cycle comprising a phosphate buffered saline wash, compressing the periosteum tissue to remove excess fluid, cryofracturing the tissue until a desired fiber size is achieved, and separating the periosteum tissue into individual periosteum fibers having the desired fiber size. Other embodiments are also disclosed.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 7, 2023
    Assignee: Allosource
    Inventors: Megan Maccagnan, Cameron Mattson, Cole Watkins, Adrian C. Samaniego, William Maslanik
  • Patent number: 11795475
    Abstract: Provided are a cell strain HEK293.CS for reducing the production of a replication competent adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace said gene fragment with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of a recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: October 24, 2023
    Assignee: CANSINO BIOLOGICS INC.
    Inventors: Tao Zhu, Haiyan Cui, Weiwei Chen, Lei Duan, Junqiang Li, Jin Ma, Chunlin Xin, Zhongqi Shao, Xuefeng Yu, Huihua Mao
  • Patent number: 11718823
    Abstract: The present disclosure relates to a novel method for rapid preparation of three dimensional (3D) spheroids/organoids, and the 3D spheroids/organoids prepared by the novel method.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: August 8, 2023
    Assignee: Purdue Research Foundation
    Inventors: Bumsoo Han, George Tsu-Chih Chiu, Cih Cheng
  • Patent number: 11634675
    Abstract: The present invention relates to an insertable culture container and a kit for three-dimensional cell culture, and a three-dimensional cell co-culture method using the same, the insertable culture container for three-dimensional cell culture comprising: a cylindrical side wall having open upper and lower portions; at least one hook protruding outward from the upper side of the side wall; and at least one support protruding inward from the lower side of the side wall. The present invention is advantageous in that air required for a three-dimensional cell culture structure can be smoothly supplied since the cell is cultured at a position spaced apart from a bottom surface of the culture container, and an existing culture plate can be used without change due to the culture container configured as an insert type.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: April 25, 2023
    Assignees: KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY, CEFO CO., LTD.
    Inventors: Dongmok Lee, Hyunsook Park, Sunray Lee